Search

Displaying results 9051 - 9060 of 10000 in total
  1. Drug

    Evixapodlin

    go.drugbank.com/drugs/DB21520
    Investigational

    Evixapodlin is under investigation in clinical trial NCT04049617 (Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Evixapodlin (Formerly GS-4224) in Participants With Advanced

  2. Drug

    SB-743921

    go.drugbank.com/drugs/DB05546
    Investigational

  3. Drug

    Teverelix

    go.drugbank.com/drugs/DB05624
    Investigational

    A synthetic decapeptide, water-soluble Gonadotropin-releasing hormone antagonist. It has reached phase II clinical trials.

  4. Drug

    Retaspimycin

    go.drugbank.com/drugs/DB05626
    Investigational

  5. Drug

    Amperozide

    go.drugbank.com/drugs/DB08927
    Experimental

    Alternatively, amperozide's main use lies in veterinary medicine, where it is typically employed to minimize aggression and stress in intensively farmed pigs. … Investigations regarding the use of the agent revolved primarily around its capability for treating schizophrenia in humans even though the drug was ultimately never clinically adopted for this indication

  6. Drug

    ASP-4058

    go.drugbank.com/drugs/DB11819
    Investigational

    ASP4058 has been used in trials studying Food Effect of ASP4058 and Pharmacokinetics of ASP4058.

  7. Drug

    Pritelivir

    go.drugbank.com/drugs/DB11844
    Investigational

    Pritelivir has been used in trials studying the prevention of HSV-2 and Genital Herpes.

  8. Drug

    P-BCMA-101

    go.drugbank.com/drugs/DB17371
    Investigational

    P-BCMA-101 is an autologous CAR-T therapy developed using Poseida’s piggyBac platform technology.

  9. Drug

    AAV-RPE65

    go.drugbank.com/drugs/DB18343
    Experimental

    AAV-RPE65 is an adenovirus associated viral vector serotype 5 containing the human RPE65 gene

  10. Drug

    WU-NK-101

    go.drugbank.com/drugs/DB18350
    Investigational

    WU-NK-101 is an allogeneic CD3-depleted, CD56-enriched activated natural killer-cell product